Precision medicine after surgery for bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether matching targeted therapy to the genetic changes in your cancer can lower the chance of it coming back after surgery. You would first have your tumor tested for specific alterations, and if one is found, you may receive a drug that targets it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You had surgery to completely remove your bile duct or gallbladder cancer.
- You have not had chemotherapy or radiation before or after your surgery.
- Your cancer shows a genetic change that one of the trial drugs can target.
- You are well enough to start treatment within about 4 to 16 weeks after surgery.
- You do not have other serious health problems or another cancer that is still active.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (tislelizumab) and chemotherapy (gemcitabine, cisplatin, S-1) given before surgery for patients with bile duct cancer that is high-risk for return or has come back within 6 months after a prior surgery. The goal is to see if this treatment can improve outcomes.
This trial tests a combination of a cancer-fighting virus (H101), a targeted therapy (lenvatinib), and an immunotherapy (toripalimab) against a standard chemotherapy (FOLFOX) for people with advanced biliary tract cancer that has progressed after one prior treatment. The goal is to see if the new combination is more effective.
This Phase 3 trial matches people with advanced bile duct cancer or gallbladder cancer to a specific targeted medicine based on their tumor’s lab results. It aims to improve disease control by using the right drug for the specific changes found in the cancer.
This trial tests a new targeted therapy, futibatinib, for people with advanced or unresectable bile duct cancer who have not had prior treatment for advanced disease. It aims to see if this drug can help shrink or control the cancer.
This trial tests different treatments for advanced bile duct or gallbladder cancer based on individual tumor features. It may help people who have not had prior therapy for their cancer.
This trial tests a combination of drugs (durvalumab, cisplatin, and gemcitabine, with or without futibatinib) given before surgery to treat intrahepatic cholangiocarcinoma—a rare cancer of the bile ducts inside the liver. The goal is to shrink the tumor and improve outcomes after surgery.
Hear when a new Biliary Tract Cancer (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.